AVA6103 (FAP-Exd)
Pancreatic Cancer, Gastric/GEJ Cancer, Cervical/Vulvar Cancer, Small Cell Lung Cancer
Key Facts
About Avacta Group
Avacta Group is an AIM-listed biotech focused on developing targeted oncology therapies that improve the therapeutic index of potent cancer drugs. Its core achievement is the pre|CISION® platform, which has demonstrated a 100:1 tumor-to-plasma drug concentration ratio in clinical trials with its lead asset, AVA6000 (FAP-doxorubicin). The strategy involves evolving the platform through three generations—from rapid-release first-gen conjugates to sustained-release and dual-payload systems—to address a broad range of solid tumors (over 90% of which express FAP) and overcome resistance mechanisms. With two clinical-stage programs and a clear pipeline, Avacta aims to redefine cancer drug delivery.
View full company profile